Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

RSV Immunisation Guidance Tool

This tool is designed to help current and future parents and caregivers as well as health care providers. It is currently based on the 2025 Western Australian RSV immunisation program.

The Kids STEM Festival 2025 – Kalgoorlie

Register now and experience an awesome adventure into the world of Science, Technology, Engineering and Mathematics this August!

Noongar language session by KalyaKoorl (Dylan Collard)

Embark on a linguistic journey with KalyaKoorl’s tailor-made Noongar Language Programs.

Funding

The Centre is committed to supporting high quality research by providing support for researchers to undertake activities of high priority to the WCVID.

New pneumococcal vaccine closes in on approval

Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.

Research

FeBRILe3: Risk-Stratification and Diagnosis of Serious Bacterial Infections in Febrile Infants Less Than 3 Months Old

Evidence-based recommendations exist for early discharge (before 48 h) of young infants with fever without source (FWS) at low risk of serious bacterial infections (SBIs). However, concerns regarding the applicability of international data to local contexts may hinder implementation. We aimed to describe the local epidemiology of FWS and evaluate a newly implemented risk-stratification guideline to support practice change.

Research

Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia

Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.

Research

Estimating the true number of people with acute rheumatic fever and rheumatic heart disease from two data sources using capture-recapture methodology

In Australia, accurate case ascertainment of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) diagnoses for disease surveillance and control purposes requires the use of multiple data sources, including RHD registers and hospitalisation records. Despite drawing on multiple data sources, the true burden of ARF/RHD is likely to be underestimated.